The ATTR Amyloidosis Treatment industry is rapidly evolving, driven by advancements in therapeutics and growing awareness of transthyretin amyloidosis (ATTR). Innovations in gene-silencing and TTR stabilizer therapies have created significant market opportunities, prompting substantial business growth among market companies. This article provides a comprehensive market analysis with an emphasis on market size, dynamic growth trends, and key market insights from 2024 to 2025.

Market Size and Overview

The ATTR amyloidosis treatment market is estimated to be valued at USD 4.14 Bn in 2025 and is expected to reach USD 7.52 Bn by 2032, growing at a compound annual growth rate (CAGR) of 8.9% from 2025 to 2032.

The increasing prevalence of hereditary and wild-type ATTR amyloidosis, coupled with continuous regulatory approvals, has expanded the market scope significantly. The rising market revenue projections underscore robust ATTR Amyloidosis Treatment Market Growth and identify key market drivers that shape industry trends.

Market Segments

The ATTR Amyloidosis Treatment market can be broadly segmented into therapy type, end-user, and region. Within therapy types, sub-segments include TTR stabilizers, gene silencers, and amyloid fibril disruptors. TTR stabilizers remain the dominant therapy with widespread clinical adoption, while gene silencers are the fastest-growing sub-segment, as evidenced by recent approvals during 2024 and 2025, including the launches of novel siRNA and antisense oligonucleotide therapies.

‣ Get more insights on :  ATTR Amyloidosis Treatment Market

‣ Get this Report in Japanese Language: ATTRアミロイドーシス治療市場

‣ Get this Report in Korean Language: ATTR아밀로이드증치료시장